Triptans and Lasmiditan Are Safe and Effective in Patients with Migraine Attacks Associated with Neurodevelopmental Disorders: A Single-Center Prospective Clinical Case Series
Abstract
Background: Triptans and lasmiditan are considered specific acute medications for migraine attacks. Despite the efficacy of these treatments, continuation of these medications is limited because some patients experience adverse effects. A previous study reported a close association between migraine and neurodevelopmental disorders. The present study investigated triptans and lasmiditan in the treatment of consecutive patients with migraine attacks accompanied by neurodevelopmental disorders. Methods: The enrolled patients were diagnosed with migraine by a certified headache specialist. Neurodevelopmental disorders were diagnosed by multiple specialists. Triptan and/or lasmiditan tablets were prescribed for all patients. Results: Triptans were effective in these patients, providing pain relief within 2 h in all patients, and twelve patients (80%) were pain-free at 2 h. However, throat discomfort was detected in two patients, and it was regarded as a minor adverse event. Lasmiditan (50 mg) was prescribed to 12 patients, and it provided pain relief in 11 patients (92%) at 2 h and rendered 7 patients pain-free (58%) at 2 h. Conversely, mild somnolence and mild dizziness were recorded in two and one patient, respectively (25%). Conclusions: In this study, triptans and lasmiditan were effective and safe in the treatment of migraine attacks accompanied by neurodevelopmental disorders. In this study, several different acute treatments were evaluated non-randomly in a small number of…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 12 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.